CHINA PHARMA HOLDINGS, INC. 8-K

What Happened
China Pharma Holdings, Inc. (through its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. or “Helpson”) announced on December 22, 2025 that it entered into a Technology Transfer Agreement with Juan Zhang, the owner of an invention patent for Ipragliflozin tablets and a method for their preparation. Under the agreement, ownership of the patent will be transferred to Helpson and the Transferor (or a designated third party) will provide technical services such as product R&D, preparation of registration materials, and assistance with registration applications. The agreed transfer price is $9.8 million, to be paid in the Company’s common stock at $1.40 per share.

Key Details

• Agreement date: December 22, 2025. Parties: Hainan Helpson Medical & Biotechnology Co., Ltd. (subsidiary) and Juan Zhang (Transferor).
• Subject: Invention patent for Ipragliflozin tablets and method for its preparation; technical services to be provided for development and registration.
• Consideration: $9,800,000 paid in common stock at $1.40 per share — equivalent to 7,000,000 shares (par value $0.001 per share).
• Reported under Item 1.01 (material definitive agreement) and Item 3.02 (unregistered sale of equity securities) of the Form 8‑K.

Why It Matters
This transaction means China Pharma acquires intellectual property and related technical support for an ipragliflozin product while conserving cash by issuing equity. The issuance of 7.0 million shares will increase the company’s outstanding share count and thus may dilute existing shareholders’ ownership percentage. For investors, the key points to watch next are any regulatory filings or development milestones related to the patent, and how the additional shares affect the company’s capital structure.